08 Aug Interius
Posted at 21:55h
in
Interius BioTherapeutics is developing an in vivo delivery bioplatform to support a pipeline of disruptive next-generation therapeutic products. Our lead program targets hematologic malignancies by generating CAR T+NK cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulation and toxic lymphodepleting chemotherapy, exploring the potential for more efficacious, safer and more broadly accessible options for patients. Interius was co-founded by Dr. Saar Gill, a hematologist-oncologist and leading scientist in the fields of cell and gene therapy at the University of Pennsylvania. The company is headquartered in Philadelphia, PA. www.interiusbio.com
